Summary
Molecular modeling studies were carried out by a combined use of conformational analysis and 3D-QSAR methods to identify molecular features common to a series of hydroxyacetophenone (HAP) and non-hydroxyacetophenone (non-HAP) peptide leukotriene (pLT) receptor antagonists. In attempts to develop a ligand-binding model for the pLT receptor, the Apex-3D program was used to identify biophoric structural patterns that are common to 13 diverse sets of compounds showing different levels of biological activity. A systematic conformational analysis was carried out to obtain sterically accessible conformations for these flexible compounds. Apex-3D was then utilized to propose common biophoric regions based on the selection of one of several conformations (MOPAC-minimized AM1) from each compound's data set that best fits the biophoric pattern and the resulting superimposition with all the other data-set compounds. Apex-3D identified three common biophoric features important for activity: one as the hydroxyl, acetyl, carbonyl and carboxyl groups, which mimic the acid-binding region of an agonist, the other as the hydrogen-bond donating site, and the third part is represented by a plane in which lipophilic aromatic groups align. The structure-activity relationships were then assessed by using the 3D-QSAR model. A common biophore model is proposed from the Apex-3D analysis which may be useful in designing new pLT antagonists. Molecular volumes and electrostatic potential similarities were also calculated in order to obtain the important structural requirements for the activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
SamuelssonB., Science, 220 (1983) 568.
LewisR.A., AustenK.F. and SobermanR.J., New Engl. J. Med., 323 (1990) 645.
CoreyE.J., ClarkD.A., GotoG., MarfatA., MioskowaskiC., SamuelssonB. and HammarstromS., J. Am. Chem. Soc., 102 (1980) 1436.
LewisR.A., DrazenJ.M., RigueiredoJ.C., CoreyE.J. and AustenK.F., Int. J. Immunopharmacol., 4 (1982) 85.
SamuelssonB., DahlenS.E., LindgrenJ.A., RouzerC.A. and SerhanC.N., Science, 237 (1987) 1171.
LewisR.A., Chest (Suppl.), 87 (1985) 55.
LeferA.M., Biochem. Pharmacol., 35 (1986) 123.
PiperD.J., In BuckleD.R. and SmithH. (Eds.) Development of Anti-Asthma Drugs, Butterworths, London, 1984, p. 174.
LewisR.A., AustenK.F. and SobermanR.J., New Engl. J. Med., 323 (1990) 645.
StenkeL., MansourM., ReizensteinP. and LindgrenJ.A., Blood, 80 (1993) 352.
ShawA., Annu. Rep. Med. Chem., 25 (1990) 61.
NakaiH., KonnoM., KosugeS., SakuyamaS., TodaM., AraiY., ObataT., KatsubeN., MiyamotoT., OkegawaT. and KawasakiA., J. Med. Chem., 31 (1988) 84.
DillardR.D., CarrP.E., KalausD.M., HaischK.D., RinkemaL.E. and FleischJ.H., J. Med. Chem., 30 (1987) 911.
MatassaV.G., MaduskuieT.P., ShapiroJr.H.S., HespB., SnyderD.W., AharonyD., KrellR.P. and KeithR.A., J. Med. Chem. 33 (1990) 1781.
GapinskiD.M., RomanC.R., RichardsonL.E. and FleischJ.M., J. Med. Chem., 31 (1988) 172.
MayD.W.P., NewtonJ.F., TorphyJ.J. and GleasonJ.G., Drugs Future, 15 (1990) 240.
SnyderD.W., GilesR.E., KeithR.A., YeeY.K. and KrellR.D., J. Pharmacol. Exp. Ther., 243 (1987) 548.
BrownJ.F., YeeY.K., CronkL.H., HebbelK.C., KrellR.D. and SnyderD.W., J. Med. Chem., 33 (1990) 1171.
HarperR.W., HerronD.K., BollingerN.G., SawyerJ.S., BaldwinR.F., RomanC.R., RinkemaL.E. and FleischJ.H., J. Med. Chem., 35 (1992) 1191.
ShawA. and KrellR.D., J. Med. Chem., 34 (1991) 1235.
GolenderV. and VorpagelE., In KubinyiH. (Ed.) 3D QSAR in Drug Design: Theory, Methods and Applications, ESCOM, Leiden, 1993, pp. 137–149.
Van deWaterbeemdH. (Ed.) Advanced Computer-Assisted Techniques in Drug Discovery, Vol. 3, VCH Publishers, New York, NY, 1994.
INSIGHT II (v. 2.3.5) 1995, Biosym Technologies, Inc., 9685 Scranton Road, San Diego, CA 92121, U.S.A.
FerenczyG.G., ReynoldsC.A. and RichardsW.G., J. Comput. Chem., 11 (1990) 159.
DewarM.J.S., ZoebiachE.G., HealyE.F. and StewartJ.J.P., J. Am. Chem. Soc., 107 (1985) 3902.
Stewart, J.J.P., MOPAC: A general molecular orbital package (v. 6.0), QCPE #455.
Biosym Technologies, Inc., San Diego, CA.
ReynoldsC.A., EssexJ.W. and RichardsW.G., J. Am. Chem. Soc., 114 (1992) 9075.
GoodA.C., HodgkinE.E. and RichardsW.G., J. Chem. Inf. Comput. Sci., 32 (1989) 3.
Myers, R.H., Classical and Modern Regression with Application, PWS-KENT Publishing Company, 1990.
SnyderD.W., GilesR.E., KeithR.A., YeeY.K. and KrellR.D., J. Pharmacol. Exp. Ther., 243 (1987) 548.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hariprasad, V., Kulkarni, V.M. A proposed common spatial pharmacophore and the corresponding active conformations of some peptide leukotriene receptor antagonists. J Computer-Aided Mol Des 10, 284–292 (1996). https://doi.org/10.1007/BF00124498
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00124498